Disclosed herein are compositions and methods for treating cancer. The methods can comprise administrating to a subject with cancer a therapeutically effective amount of an oncolytic virus and a therapeutically-effective amount of a nuclear export inhibitor. Methods disclosed herein can convert nonpermissive or semi-permissive cancers to permissive cancers that are susceptible to infection and killing by oncolytic viruses.

An oncolytic poxvirus encoding a truncated human CD19 is used in conjunction with a chimeric antigen receptor to treat solid tumors.

Disclosed are a therapeutic agent comprising a labeling polypeptide introduced into a tumor cell and a multispecific antibody capable of binding to and recognizing the labeling polypeptide, the multispecific antibody, a kit comprising the therapeutic agent, and use of the therapeutic agent or the multispecific antibody in the manufacture of a medicament for treating a tumor and/or a cancer.

A method of reducing an APOE 4 mediated cognitive deficit is provided and comprises administering to a subject in need thereof an effective amount of a recombinant vaccinia virus complement control protein (hrVCP) polypeptide having a modified amino acid sequence including one or more amino acid substitutions to an amino acid sequence as set forth in SEQ ID NO: 2, wherein the one or more amino acid substitutions are selected from the group consisting of H98Y, E102K, E108K, E120K, and combinations thereof, provided at least one of the substitutions is E102K. Methods of treating dementia characterized by an APOE 4 mediated cognitive deficit and methods of reducing complement activation mediated by APOE 4 are further provided an include administration of the hrVCP polypeptide.

An oncolytic poxvirus encoding a truncated human CD19 is used in conjunction with a chimeric antigen receptor to treat solid tumors.

Disclosed herein are compositions and methods for treating cancer. The methods can comprise administrating to a subject with cancer a therapeutically effective amount of an oncolytic virus or modified oncolytic virus and a therapeutically-effective amount of a nuclear export inhibitor. Methods disclosed herein can convert nonpermissive or semi-permissive cancers to permissive cancers that are susceptible to infection and killing by oncolytic viruses or modified oncolytic viruses.

The disclosure provides Myxoma virus that expresses one or more immunomodulatory transgenes and its use in inhibiting and/or treating a hematological cancer in a subject. The disclosure also provides a leukocyte having a Myxoma virus that expresses one or more immunomodulatory transgenes and the use of the leukocyte for inhibiting and/or treating a hematological cancer in a subject.